Aligos Therapeutics, Inc. (ALGS) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $18.30M | -50.5% |
| 2024 | $37.00M | -72.7% |
| 2023 | $135.70M | +66.8% |
| 2022 | $81.35M | -56.5% |
| 2021 | $186.82M | -15.2% |
| 2020 | $220.38M | +216.8% |
| 2019 | $69.56M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $18.30M | -50.5% |
| 2024 | $37.00M | -72.7% |
| 2023 | $135.70M | +66.8% |
| 2022 | $81.35M | -56.5% |
| 2021 | $186.82M | -15.2% |
| 2020 | $220.38M | +216.8% |
| 2019 | $69.56M | — |